Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis Patients

This study has been completed.
Information provided by (Responsible Party):
Bausch & Lomb Incorporated Identifier:
First received: August 2, 2010
Last updated: December 4, 2013
Last verified: December 2013
The purpose of this study is to study the safety and efficacy of bepotastine besilate ophthalmic solution in allergic conjunctivitis patients.

Condition Intervention Phase
Allergic Conjunctivitis
Drug: bepotastine besilate ophthalmic solution
Drug: placebo comparator ophthalmic solution
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Bausch & Lomb Incorporated:

Primary Outcome Measures:
  • Rhinoconjunctivitis quality of life questionnaire [ Time Frame: Day -7 to Day 14 ]

Enrollment: 240
Study Start Date: June 2010
Study Completion Date: December 2010
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Bepotastine Besilate Ophthalmic Solution Drug: bepotastine besilate ophthalmic solution
sterile ophthalmic solution
Placebo Comparator: Placebo Drug: placebo comparator ophthalmic solution
sterile ophthalmic solution


Ages Eligible for Study:   12 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects 12 years of age and older with 2-year history of allergic conjunctivitis

Exclusion Criteria:

  • No active ocular or nasal infection
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01174823

United States, California
ISTA Pharmaceuticals, Inc.
Irvine, California, United States, 92618
Sponsors and Collaborators
Bausch & Lomb Incorporated
Study Director: Tim McNamara, PharmD ISTA Pharmaceuticals, Inc.
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Bausch & Lomb Incorporated Identifier: NCT01174823     History of Changes
Other Study ID Numbers: S00041
Study First Received: August 2, 2010
Last Updated: December 4, 2013

Additional relevant MeSH terms:
Conjunctivitis, Allergic
Conjunctival Diseases
Eye Diseases
Hypersensitivity, Immediate
Immune System Diseases
Pharmaceutical Solutions
Ophthalmic Solutions processed this record on May 25, 2017